Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
Authors:
- Jeffrey E. KropfJKJeffrey E. Kropf
- Tony LeeTLTony Lee
- Peter BlomgrenPBPeter Blomgren
- Jianjun XuJXJianjun Xu
- Zhongdong ZhaoZZZhongdong Zhao
- J. Andrew WhitneyJWJ. Andrew Whitney
- Deborah MaclinDMDeborah Maclin
- Patricia MaciejewskiPMPatricia Maciejewski
- Ann Marie RossiARAnn Marie Rossi
- 29 April 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (9) , 3856-3873
Abstract
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.Keywords
This publication has 49 references indexed in Scilit:
- Carboxylic Acid (Bio)Isosteres in Drug DesignChemMedChem, 2013
- Discovery and Development of Spleen Tyrosine Kinase (SYK) InhibitorsJournal of Medicinal Chemistry, 2012
- Diverse phosphorylation patterns of B cell receptor-associated signaling in naïve and memory human B cells revealed by phosphoflow, a powerful technique to study signaling at the single cell levelFrontiers in Cellular and Infection Microbiology, 2012
- Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2011
- Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesisLeukemia, 2011
- Therapeutic Targeting of Syk in Autoimmune DiabetesThe Journal of Immunology, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established GlomerulonephritisJournal of the American Society of Nephrology, 2010
- Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic targetBlood, 2009
- The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2003